TARS

Tarsus Pharmaceuticals, Inc. (TARS) - 10-Q Summary for Period Ended June 30, 2026

Business Context and Reporting Period

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on eye care therapeutics. The company's primary commercial product is XDEMVY (lotilaner ophthalmic solution) 0.25%, approved by the FDA in July 2023 for the treatment of Demodex blepharitis. The company also maintains a pipeline of product candidates, including TP-04 for ocular rosacea and TP-05 for Lyme disease prophylaxis. This report covers the quarterly period ended June 30, 2026.

Key Financial Metrics

Material Changes vs. Prior Comparable Period

• Revenue Growth: Total revenues increased significantly year-over-year. For the three months ended June 30, 2026, revenues rose to $173.9 million from $102.7 million in the prior year period (a 69% increase). For the six months, revenues reached $336.0 million compared to $181.0 million in the prior year (a 76% increase). This growth was driven by higher XDEMVY sales volume and improved gross-to-net discounts.
• License Revenue: The six-month period included $16.7 million in license fees and collaboration revenue, primarily from a $15.0 million regulatory milestone payment triggered by the approval of TP-03 in China. No such revenue was recognized in the prior year six-month period.
• Expense Increases: Operating expenses increased substantially due to commercial expansion and R&D activities. Selling, general, and administrative (SG&A) expenses rose by $47.7 million (Q2) and $99.1 million (YTD) compared to the prior year, driven by increased marketing, patient support, and personnel costs. R&D expenses increased by $15.4 million (Q2) and $23.4 million (YTD), largely due to the initiation of the Calliope Trial for TP-05.
• Net Loss Improvement: Despite higher expenses, the net loss narrowed to $18.6 million for Q2 2026 from $20.3 million in Q2 2025, and to $25.5 million for the six months ended June 30, 2026, from $45.5 million in the prior year period.

Guidance, Outlook, and Management Commentary

• Commercialization: Management highlights strong adoption of XDEMVY, with the number of Eye Care Professionals (ECPs) prescribing the drug five or more times per week doubling year-over-year. Direct-to-consumer (DTC) initiatives, including a celebrity campaign, have increased unaided awareness of Demodex blepharitis to approximately 30%.
• Pipeline Progress:
  • TP-04 (Ocular Rosacea): The Phase 2 KORE Trial was initiated in December 2025, with topline results expected in the first half of 2027.
  • TP-05 (Lyme Disease): The Phase 2 Calliope Trial enrollment was completed in March 2026, with topline results expected in the first half of 2027.
  • IRX-101 (Retina): Acquired via the iRenix Medical acquisition in July 2026. The Phase 3 COMFORT Trial is expected to begin enrolling in the first half of 2027.
• Liquidity and Capital Resources: As of June 30, 2026, the company held $449.7 million in cash and marketable securities. Management believes existing resources, combined with expected proceeds from a private placement (PIPE) transaction, are sufficient to fund operations for at least the next 12 months.
• Subsequent Events:
  • iRenix Acquisition: Completed on July 6, 2026, for $37.5 million in cash and 607,093 shares of common stock.
  • Alkeus Acquisition: Entered into a definitive agreement on July 31, 2026, to acquire Alkeus Pharmaceuticals for $270.0 million in cash and $180.0 million in stock, subject to closing conditions.
  • PIPE Transaction: Entered into an agreement on August 5, 2026, to raise approximately $125.0 million in gross proceeds, expected to close on August 7, 2026.

Key Facts for Investor Verification

• Customer Concentration: For the six months ended June 30, 2026, two customers accounted for 76.8% of total gross product sales. These same two customers represented 71.7% of accounts receivable as of June 30, 2026.
• Supply Chain Risk: The company relies on single-source suppliers for the active pharmaceutical ingredient (API) for XDEMVY and for certain materials for its product candidates.
• Debt Obligations: The company has a $75.0 million credit facility with Pharmakon Advisors, LP, maturing in April 2029, with an effective interest rate of 11.75% as of June 30, 2026. The debt is collateralized by substantially all company assets.
• Intellectual Property: The commercialization of XDEMVY and pipeline candidates depends on licenses from Elanco Tiergesundheit AG. Termination of these agreements could severely impact operations.
• Regulatory Risks: The company faces potential risks related to FDA scrutiny of direct-to-consumer advertising and evolving healthcare pricing regulations, including the Inflation Reduction Act and state-level price controls.